

# KRN-633

Catalog No: tcsc0220

Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

**Size:** 100mg

**Specifications** 

CAS No:

286370-15-8

Formula:

 $\mathsf{C}_{20}\mathsf{H}_{21}\mathsf{CIN}_4\mathsf{O}_4$ 

**Pathway:** Protein Tyrosine Kinase/RTK

Target: VEGFR

## Purity / Grade:

>98%

#### Solubility: DMSO : $\geq$ 8 mg/mL (19.19 mM)

# **Observed Molecular Weight:**

416.86

### **Product Description**


KRN-633 is a potent **VEGFR** inhibitor with **IC**<sub>50</sub>s of 170, 160 and 125 nM for VEGFR1, VEGFR2 and VEGFR3, respectively.



IC50 & Target: IC50: 170 nM (VEGFR1), 160 nM (VEGFR2), 125 nM (VEGFR3)<sup>[1]</sup>

In Vitro: KRN-633 inhibits tyrosine phosphorylation of VEGFR-1, VEGFR2, c-Kit, and PDGFR- $\beta$  (IC<sub>50</sub>=11.7, 1.16, 8.01, 130 nM) in human umbilical vein endothelial cells. KRN-633 also inhibits the VEGF-driven proliferation of HUVECs (IC<sub>50</sub>=14.9 nM). KRN-633 suppresses capillary tube formation of endothelial cells<sup>[1]</sup>.

*In Vivo:* KRN-633 inhibits tumor growth in several tumor xenograft models with diverse tissue origins, including lung, colon, and prostate, in athymic mice and rats. KRN-633 also causes the regression of some well-established tumors and those that have regrown after the cessation of treatment. KRN-633 is well tolerated and has no significant effects on body weight or the general health of the animals. Histologic analysis of tumor xenografts treated with KRN-633 reveals a reduction in the number of endothelial cells in non-necrotic areas and a decrease in vascular permeability<sup>[1]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!

Copyright 2021 Taiclone Biotech Corp.